Somewhat Positive Press Coverage Somewhat Unlikely to Impact Bio-Rad Laboratories (BIO) Stock Price
News stories about Bio-Rad Laboratories (NYSE:BIO) have been trending somewhat positive on Tuesday, according to Accern. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bio-Rad Laboratories earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 47.0206625957367 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- IDEXX Laboratories Gains on Solid Prospects & CAG Business (zacks.com)
- Automated Immunoassay Analyzers Market to be valued at US$3.78 bn by the end of 2025 (openpr.com)
- Here’s Why You Should Invest in Bio-Rad (BIO) Right Now (msn.com)
- Veeva Systems Vault Clinical Platform to Aid Ora's Operations (finance.yahoo.com)
- Surface Plasmon Resonance Market to Reach US$ 1273.8 Mn in Revenues in 2027 (prnewswire.co.uk)
Bio-Rad Laboratories (BIO) traded down $2.90 during trading hours on Tuesday, reaching $270.94. The company had a trading volume of 68,450 shares, compared to its average volume of 174,338. Bio-Rad Laboratories has a twelve month low of $194.01 and a twelve month high of $279.59. The firm has a market cap of $8,158.33, a price-to-earnings ratio of 71.11, a P/E/G ratio of 2.34 and a beta of 0.89. The company has a quick ratio of 2.75, a current ratio of 3.93 and a debt-to-equity ratio of 0.15.
Bio-Rad Laboratories announced that its Board of Directors has authorized a stock repurchase plan on Tuesday, November 28th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the medical research company to buy shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its shares are undervalued.
A number of research analysts recently issued reports on BIO shares. Citigroup boosted their price objective on Bio-Rad Laboratories to $325.00 and gave the company a “buy” rating in a research report on Wednesday, February 28th. Wells Fargo & Co reduced their price objective on Bio-Rad Laboratories from $290.00 to $280.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. CL King lowered Bio-Rad Laboratories from a “buy” rating to a “neutral” rating in a research report on Friday, February 16th. TheStreet upgraded Bio-Rad Laboratories from a “c+” rating to a “b-” rating in a research report on Monday, November 13th. Finally, Jefferies Group boosted their price objective on Bio-Rad Laboratories to $325.00 and gave the company a “buy” rating in a research report on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $295.20.
In other Bio-Rad Laboratories news, CFO Christine A. Tsingos sold 4,980 shares of Bio-Rad Laboratories stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $249.40, for a total transaction of $1,242,012.00. Following the sale, the chief financial officer now owns 7,283 shares of the company’s stock, valued at approximately $1,816,380.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 28.29% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Bio-Rad Laboratories (BIO) Stock Price” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2018/03/14/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-bio-rad-laboratories-bio-stock-price-2.html.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.